Moyom 生物技术公司与WPP合作在全球扩大Aphranel, 其CAHA可注射。 Moyom Biotech partners with WPP to expand Aphranel, its CaHA injectable, globally.

Moyom生物技术公司与全球通讯公司WPP集团合作,扩大Aphranel的国际存在,Aphranel是以CaHA为基础的注射美学产品。 Moyom Biotechnology has partnered with global communications firm WPP Group to expand the international presence of Aphranel, its CaHA-based injectable aesthetic product. 合作的重点是推动Aphranel的 " 时代的动力 " 品牌哲学,强调科学、结构支持和长期成果。 The collaboration focuses on advancing Aphranel’s “Poetics of Time” brand philosophy, emphasizing science, structural support, and long-term results. WPP将利用其全球创造性、媒体和大赦国际的专长,在市场上建立一致的品牌叙事。 WPP will use its global creative, media, and AI expertise to build a consistent brand narrative across markets. Aphranel经中国批准,被定位为麻醉药物的再生解决办法,Moyom还通过在泰国和2025年IMCAS中国的教育活动加以推广。 Aphranel, approved in China, is positioned as a regenerative solution for aesthetic medicine, with Moyom also promoting it through educational events in Thailand and IMCAS China 2025.